Who holds the capivasertib patents, and what are they protecting?
Capivasertib (an investigational AKT inhibitor) is covered by multiple patent families held by different assignees across different jurisdictions, typically aimed at one or more of the following: the compound itself (and close analogs), specific formulations, and medical-use claims such as treating particular cancers. Patent coverage can vary by country because prosecutions and claim scopes differ by region.
What patents exist for capivasertib, and how do I find them?
A practical way to identify relevant capivasertib patents is to search patent databases by:
- Name and synonyms (capivasertib; also related spellings/identifiers)
- Related compound identifiers (e.g., development codes if shown in publications)
- Assignee/holder names used in related drug-development papers
- Patent families cited in regulatory dossiers or scientific articles
Key databases to check include:
- Google Patents (fast for full-text searching)
- Espacenet (EPO coverage)
- The USPTO database (US filings and prosecution history)
- WIPO PATENTSCOPE (international applications)
When does capivasertib patent protection expire?
Patent expiry depends on the specific patent’s filing date, jurisdiction, and any patent-term adjustments. In general, patents for small-molecule drugs typically aim for about 20 years from the earliest priority date, but real-world “protected time” is affected by:
- Different priority dates within the same patent family
- Country-by-country filing and grants
- Possible patent term extensions or supplementary protections (where available)
- Additional patents covering new indications, combinations, or formulations
Because capivasertib has likely multiple overlapping patent families, you can’t use one date for “the capivasertib patent.” Expiry is usually determined per patent (and per country).
Can generics enter before capivasertib’s patents expire?
In most jurisdictions, generic (or biosimilar—though capivasertib is a small molecule) entry is tied to patent and exclusivity status. If any granted patents remain in force for the relevant claim scope (compound, method of use, or combination therapy), generic approval or launch can be delayed by legal barriers such as:
- Patent “listed” status in relevant regulatory systems
- Litigation or settlement agreements
- Design-around patents that attempt to avoid infringement
The exact answer for capivasertib depends on which patents are still active in the target country and whether they cover the intended generic product’s claims (including dosing and therapeutic use).
Are there litigation or challenges that affect capivasertib patent enforceability?
Drug patent enforceability can change due to:
- Court rulings invalidating claims
- Narrowing claim scope through litigation
- Settlement agreements that establish “launch at” dates
- Challenges to claim interpretation (what constitutes infringement)
To assess the current litigation landscape, you typically need to check:
- Country-specific court dockets
- Patent challenge filings tied to regulatory submissions
- News and filings for any AKT inhibitor competitor seeking market entry
How do capivasertib patents relate to specific combinations or indications?
Companies often file additional “evergreen” patents around:
- New patient subsets or biomarkers
- New lines of therapy
- Specific combination regimens with other drugs
- New dosing schedules or formulations
So even if the “core compound” patent is close to expiry, combination/indication patents may extend protection for certain uses.
What competitors are relevant to capivasertib patent questions?
Competitors matter because patent landscapes are shaped by parallel drug programs in the same pathway (AKT inhibitors) and by generic strategies that attempt to avoid infringement. The most relevant comparison is usually not one-to-one “which drug has a later patent,” but:
- Which patents block generic entry in each country for capivasertib specifically
- Whether competitors target similar indications with different claimed mechanisms or formulations
What should I do if I need the exact capivasertib patent numbers and claims?
If you tell me the country (e.g., US, EP/UK, JP, CN) and whether you care about compound, formulation, or a specific indication/combination, I can narrow the search approach to the right patent families and map them to likely expiry windows.